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1. Introduction
Despite the most unflattering epithets and fear, pain was and still remains the normal response
of any living organism on strong physical, chemical or mechanical stimuli. It has the most
important protection function in nature – at just the right time pain immediately signals about
appearance of exogenic or endogenic destructive effects on a certain organ [1-6], and it is simply
necessary for the organism’s survival as a biological unit. Unfortunately, it presents not only
by disagreeable sensation. Being rather complex psychophysiological phenomenon pain
(especially strong and continued) is often accompanied by very powerful emotional stresses
[7-9], which can rapidly exhaust the body’s adaptation resources and cause the serious
disorders of its vital functions. Obviously it is for this reason that International Association for
the Study of Pain considers pain as a global factor causing problems in modern society not
only of medical, but also of socio-economic character [10-13].
Pains of various origin and pain syndromes occur so often as it is difficult to find a person
among the world population that does not know this feeling. Hence it is not surprising that
pain-killers are among the most popular and often used drugs. The drug arsenal of this
pharmacological group that is available in modern medicine is exceedingly wide [14].
However, even under such conditions the appropriate pain relief is not always successful. The
cause of it can be side effects and, as a consequence, numerous contraindications and restric‐
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tions in using drugs [15]. That is why the vital task of pharmaceutical and medical chemistry
is the search of new, highly effective and, most notably, safe pain-killers.
Quinoline as a basic structure of such investigations is of special interest. The precondition of
it is the natural origin, practically unlimitted synthetic potential and, of course, the analgetic
action, which is inherent to many of its derivatives. For example, quinine (1, Figure 1) – the
main alkaloid of cinchona tree bark – does not only inhibit malaria parasites actively, but
reveals nonspecific analgesic properties. It potentiates the action of narcotic and nonnarcotic
analgesics, thanks to which it has been widely used in the composition of finished drug
combinations for headache. Lysergic acid diethylamide (2, more known under abbreviation
LSD) created semisynthetically as a vigorous psychodelic is currently prohibited to therapeutic
use by the laws in most countries. Nevertheless, in spite of its illegal status, researchers
continue to be interested in LSD because of its unique medicinal properties. In particular, it
has been found that as an analgesic this substance acts more effectively and sustained than
opiates in low doses that do not cause any psychologic effects. And as for inhibition of cluster
headaches – a rare syndrome causing particularly intensive pain, it has no equal at all for the
present [16].
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Figure 1. Natural (1), semisynthetic (2) and synthetic (3 and 4) quinoline analgesics
Natural resources are limited and not always reproducible. Besides, isolation of biologically
active substances from the plant or animal raw material, their subsequent purification and
standardization is, as a rule, difficult and time-consuming. That is why it is quite natural that
the search of new analgesics of the quinoline Internet resources reveals a lot of publications
concerning the given topics [17-23]. Thus, promising substances are created based on various
derivatives both quinoline (3) itself and its hydrogenized analogs (4).
2. Synthesis and analgesic activity of 1-allyl-4-hydroxy-6,7-dimethoxy-2-
oxo-1,2-dihydroquinoline-3-carboxylic acid N-R-amides
Until recently 4-hydroxyquinolin-2-ones have not even mentioned as analgesics in scientific
literature. Only some years ago the situation turned over when based on preliminary virtual
screening we obtained hydrochlorides of [(alkylamino)alkyl]amides of 1-allyl-4-hydroxy-6,7-
dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid as potential opioid receptor antago‐
nists [24]. Further pharmacological research has confirmed the presence of “calculated”
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biological properties of the compounds synthesized. At the same time it has been noted that
some substances do not block the pain-killing action of narcotic analgesics, but vice versa,
prolong it greatly. It is this obsevation that has become the first step for conducting extensive
studies in purposeful research of substances with a new type of the pharmacological effect on
a living organism for this class of compounds, i.е. potential pain-killers, in the range of 4-
hydroxyquinolin-2-ones derivatives.
The beginning of this big and complex work was the synthesis of 1-allyl-4-hydroxy-6,7-
dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid alkyl-, hydroxyalkyl-, cyclo-alkyl-,
arylalkyl- and hetarylalkylamides (6, Figure 2) carried out by the reaction of methyl 1-allyl-4-
hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxylate (5) with the corresponding
primary amines in boiling methanol [25, 26].
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Figure 2. Synthesis of 1-allyl-6,7-dimethoxy-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides (6)
The screening test of analgesic properties of 1-N-allylsubstituted amides 6 convinced us in
correctness of the chosen direction – each and all compounds revealed the analgesic effect to
a greater or lesser degree in oral introduction to white rats in the dose of 0.00005 Mol/kg (on
the average it is approximately 20 mg/kg) [25, 26]. While carrying out the biological experi‐
ments the animals were treated in accordance with the European Convention for Protection
of Vertebrate Animals used for Experimental and Other Scientific Purposes. Of 50 samples
studied with the general formula 6 approximately half of them do not yield Diclofenac in
activity, and three of them (6, R = -(CH2)2OH, -CH2C6H4-Cl-4 or furfuryl) even exceed one of
the most powerful nonnarcotic analgesics Ketorolac. In the experiments of the given series the
standard model of rectal mucosa irritation by electric current was used. Therefore, the central
component influencing on the nociceptive system is present in the mechanism of the analgesic
action of amides 6. One regularity that can be interesting for future research has come to our
attention. It is clearly traceable in all groups of compounds with the same aromatic ring in the
arylalkylamide fragment, e.g., benzyl- → 2-phenylethyl- → 3-phenylpropylamide; 4-chloro‐
benzyl- → 2-(4-chlorophenyl)ethylamide, etc. It appeared that the farther the aromatic
substituent from the amide nitrogen atom is, the less are the analgesic properties of the
corresponding 1-allyl-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic
acid arylalkylamides.
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3. Chemical modification of 1-allyl-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-
dihydroquinoline-3-carboxamides
After revealing a new biological activity in compounds of any chemical class usually the
complex of works directed to improvement of their pharmacological and(or) pharmaceutical
properties follows. This methodology being generally recognized and traditional for medical
chemistry consists in gradual introduction of various structural modifications into a basic
molecule allowing to have changes in its characteristics in the right direction. We tried to
implement such approach in practice in our further research; by its result the theoretically
important regularities of the “structure – activity” relationship at least can be determined. And
if one is fortunate (the element of chance is always present in such works), it is realistic to reveal
the promising lead compounds with a practical significance concerning the solution of the
problem dealt with.
3.1. Halocyclization in 2-bromomethyl-7,8-dimethoxy-5-oxo-1,2-dihydro-5H-oxazolo[3,2-
a]quinoline-4-carboxamides
The ability of 1-N-allylsubstituted 4-hydroxyquinolin-2-ones to cyclize readily in oxazoloqui‐
nolines [27] while interacting with the molecular bromine in acetic acid was used by us for
transformation of amides 6 described above into their tricyclic derivatives 7 (Figure 3). This
interesting reaction occurs instantly and quantitatively, but its direction is insensitive to the
structure of substituents and it always primarily occurs as bromocyclization [28, 29]. Never‐
theless it should be remembered that carrying out such reactions requires the strict observance
of the equimolar ratio of reagents. It is clear that the lack of bromine will lead to partial
transformation of allyl derivatives 6 into oxazoloquinolines 7. However, the excess of bromine
is also inadmissible since in this case formation of complexes of di(2-bromomethyl-5-hy‐
droxy-7,8-dimethoxy-4-R-carbamoyl-1,2-dihydrooxazolo[3,2-a]quinolinium) ditribromides
with bromine [25] or (if there is structural background for it) bromination of the molecule’s
amide fragment are possible [26].
According to the data of the biological research transfer from bicyclic 1-allyl-4-hydroxy-6,7-
dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamides 6 to their tricyclic oxazoloquinoline
derivatives 7 as such does not have a significant effect on analgesic properties and, therefore,
it is not likely to be considered practical. Nevertheless, rather high reactivity of 2-bromomethyl
oxazol fragment of these compounds in relation to various nucleophiles allows conducting
more profound transformation into 2-aminomethyl- (8) or 2-methylene- (9) oxazoloquinolines
that have not studied yet pharmacologically and even into 1-acetonyl derivatives (10) [27].
Taking into account immensely wide synthetic possibilities the probability of success in future
studies concerning these directions remains at the very high level.
3.2. 1-N-Allyl group removal
The next variant of the chemical modification of 1-allyl-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-
dihydroquinoline-3-carboxamides  (6)  was  obvious  and  simple  removal  of  1-N-allyl
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substituent from the basic molecule. More specifically, obtaining of the target products only
externally looks like removal of 1-N-allyl fragment. In reality the first stage of alkylation
for initial methyl 4,5-dimethoxyanthranilate is simply excluded from the synthetic scheme
of amides 6 obtaining [30].
Lower esters of 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acids have a high reac‐
tivity [31-34]; due to it their transformation into various N-R-amides usually causes no
complications. That is why problems arosen in amidation of dimethoxy substituted ester 11
by primary alkylamines appeared to be unexpected to a great extent. For example, after the
synthesis in boiling DMF used because of the low solubility of ester 11 in other organic solvents,
along with target alkylamides 12 formation of a noticeable amount of 4-hydroxy-6,7-dime‐
thoxy-1H-quinoline-2-one was observed (13). The cause of appearance of this admixture
proved to be water present in the reaction mixture; its effect could be eliminated by amidation
at the temperature of about 80 °С. As a result a great number of target alkyl-, hydroxyalkyl-,
cyclo-alkyl- and arylalkylamides of 4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-
carboxylic acid (12, Figure 4) have been obtained with high yields and purity [35, 36]. Anilides
and hetarylamides 12 do not form in these conditions. The more rigid conditions are necessary
for their synthesis such as the temperature of approximately 120 °С and quite little amount of
DMF (1-2 ml per 0.01 mol) [37, 38]. It is of interest that in a greater volume of the solvent
amidation of alkyl 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylates by anilines and
hetarylamines takes place incredibly slow.
The analgesic activity of seventy 4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-
carboxamides in empty position 1 with the general formula 12 has been studied in white mice.
In the experiments the classical model of ”acetic acid induced writhing” [39] allowing to
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Figure 3. Synthesis and chemical transformations of 2-bromomethyloxazolo[3,2-a]quinoline-4-carboxamides (7)
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estimate the peripheral component of the pain relieving effect of the tested samples has been
used. We immediately note that simplification of the structure of the objects under research
initiated by us did not affect their biology cardinally – in this set of experiments there were no
examples of complete or substantial loss of analgesic properties.
MeO
MeO N
H
O
OH
COOMe MeO
MeO N
H
O
OH
CONH-R MeO
MeO N
H
O
OH
11 12
H2N-R
13
+
Figure 4. Synthesis of 4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamides (12)
Most alkylamides 12 demonstrate a moderate and statistically significant (р ≤ 0.05) analgesic
effect comparable with Piroxicam at the same dose (20 mg/kg, orally) [35]. Hydroxyl or alkoxyl
groups at the terminal carbon atom of amide fragments only decrease the activity. And transfer
from alkylamides with the normal structure to their cyclic analogs is not so unambiguous. For
example, in the case of propyl derivatives the transformation mentioned is accompanied with
almost complete loss of analgesic properties. However, with prolongation of alkyl chains the
effect changes to the opposite one – cyclo-pentyl - and cyclo-hexylamides 12 are more active
than their acyclic analogs. Of all the group of alkyl-, hydroxyalkyl- and cyclo-alkylamides only
propylamide (12, R = Pr) is worthy. It has demonstrated the better results on the ”acetic acid
induced writhing” model than Piroxicam, and even than more effective drugs Nabumetone
and Diclofenac.
Arylalkylamides 12 are of much greater interest. Many of them do not yield, and some of them
even exceed generally accepted analgesics used in tests by their analgesic action in much lower
doses [36]. Thus, the structural biological regularity found while studying 1-N-allylsubstituted
amides 6 has been confirmed once more, namely, with introduction of the aryl ring into the
alkylamide fragment the activity increases, but with its moving from the nitrogen amide atom
it gradually decreases.
Involvement of new classes of compounds, in particular anilides (12, R = Ph or substituted Ar)
[38], in the range of the objects under research has supplemented this regularity with one more
observation that is important for future investigations – the total absence of any methylene
bridge between nitrogen amide atom and aryl substituent reflects negatively on analgesic
properties.
In the group of hetarylamides only pyridine derivatives (12, R = Py or 2-Py-Me) [37] synthe‐
sized as structurally related carbonyl analogs of Piroxicam have been studied. The biological
testing of these compounds has shown that the majority of them are approximately equal to
Piroxicam by the level of their analgesic activity. In the range of isomeric unsubstituted
pyridylamides a distinct dependence of their analgesic action on the position of the nitrogen
atom in the pyridine fragment: 3 < 4 < 2 is observed. In the next group of isomers – monomethyl
substituted pyridyl-2 amides – there are somewhat different regularities: although С-methyl‐
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ation of the pyridine ring promotes intensification of analgesic properties, however, in general,
the effect appears to be insignificant and, furthermore, with low sensitivity to the methyl group
position.
Hetarylalkylamides of 4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic
acid (12, R = picolyl-2, 3 or 4; furfuryl or tetrahydrofurfuryl) should be particularly mentioned.
The bioisosteric replacements methodology [40-43] used in medical chemistry fruitfully and
for a long period of time was the theoretical background for the synthesis of these compounds.
In classic case implementation of this approach is replacement of an atom or a group of atoms
with another ones having approximately the same size, shape and similar electronic configu‐
ration [44]. It is expected that after such modification a substance will possess the biological
effect, which is close to the initial structure, and, probably, the more expressed one [45]. Based
on these particular considerations we substituted the phenyl ring in the most active compound
studied – N-benzyl-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide
(12, R = CH2Ph) – by pyridinic or furan nuclei being isosteric to it. According to the results of
pharmacological studies transfer to tetrahydrofuran and especially furan derivatives has been
recognized as unsuccessful as it led to the marked loss of the analgesic activity. But Ph → Py
replacement appeared to be really bioisosteric. Moreover, in this case the strength of the effect
is determined by the position of a heteroatom in the pyridinic cycle: 4-Py ≤ Ph = 2-Py < 3-Py.
A significant enhancement of analgesic properties of N-(3-pyridylmethyl)-4-hydroxy-6,7-
dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide (12, R = CH2Py-3) was a solid argu‐
ment for choosing it as a lead compound at the given stage of our research.
3.3. Modification of the benzene moiety of quinolone ring
The next fragment of our research is devoted to making modifications into benzene and (or)
other moieties of the quinolone ring only exclusively by the lead compound (Figure 5).
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Figure 5. Structural analogs of the lead compound modified in benzene and other moieties of the quinolone ring
Pharmacological testing of this group of substances (Table 1) has demonstrated that on the
model of ”acetic acid induced writhing” with oral administration in the dose of 20 mg/kg they
all are highly active analgesics, which do not yield or exceed the known drugs taken in the
doses that correspond to their ED50 [46]. Therefore, there is every reason to believe that
generally substituents in the quinolone ring affect weakly the analgesic properties of 4-
hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides. Nevertheless, N-(3-pyridylmethyl)-4-
hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide has still retained its
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leading positions. In particular, it has been found that removal of one methoxy group from its
molecule (amides 14a,b), as well as 1-N-ethylation (amide 14j) result in some decline of
analgesic properties. Halogens in the benzene moiety of the molecule (amides 14c-i) cause the
similar effect; therefore, their presence should be also admitted as undesirable. The exception
is only 6-bromine derivative 14g appeared to be even somewhat more active than the lead
compound. But in the whole, increase of the activity is quite negligible (see Table 1). In addition,
in this case it is necessary to consider the possible increase of toxicity due to the presence of a
halogen atom in the molecule.
Compound R R'
Analgesic activity
(decrease in the
amount of "acetic acid
writhing", %)
Compound R R'
Analgesic activity
(decrease in the
amount of "acetic
acid writhing", %)
14a H 6-OMe 64.3 14k H H 70.6
14b H 7-OMe 60.2 14l Me H 61.4
14c H 6-F 51.2 14m Et H 50.2
14d H 6,7-F2 48.6 14n All H 75.9
14e H 6-Cl 54.6 14o Pr H 74.3
14f H 7-Cl 67.9 14p Bu H 63.1
14g H 6-Br 78.3 14q i-Bu H 59.0
14h H 6,8-Br2 54.2 14r Am H 57.8
14i H 6-I 69.7 15 – – 45.0
14j Et 6,7-(OMe)2 63.4 16 – – 80.7
Lead compound (20 mg/kg) 75.3 Metamizole sodium (55 mg/kg) 35.1
Piroxicam (20 mg/kg) 34.5 Diclofenac (5 mg/kg) 51.6
Piroxicam (92 mg/kg) 50.0 Nabumetone (50 mg/kg) 50.7
Table 1. The analgesic properties of picolyl-3-amides 14-16 on the the "acetic acid induced writhing" model (p ≤ 0.05)
Cheap and more available synthetically picolyl-3-amides without substituents in the benzene
moiety of the molecule (14, R' = H), especially 1-N-allyl (14n) and 1-N-propyl (14o) derivatives,
demonstrated excellent indices. However, separation of 3-carboxamide and quinolone
fragments by the methylene bridge, i.e. transfer to N-(3-pyridylmethyl)-2-(4-hydroxy-2-
oxo-1,2-dihydro-3-quinolinyl)acetamide (15), influences on the analgesic activity negatively.
According to the results of the primary screening it should be recognised that the most
successful chemical modification of the lead compound is removal of both methoxy groups
with the simultaneous reduction of the benzene moiety of the quinolone ring – N-(3-pyridyl‐
methyl)-4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide (16) appeared to be
the most powerful analgesic of the given group. Unfortunately, after thorough analysis of all
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the pros and cons we had to refuse the further study of some highly reactive compounds for
various reasons. Amides 14k-r, for instance, were published earlier as objects for searching
antituberculous drugs [47]. Therefore, their proper patent protection as analgesics is already
impossible in principle. In case of hexahydroderivative 16 we faced another problems that
were more serious.
3.4. Polymorphism of N-(3-pyridylmethyl)-4-hydroxy-2-oxo-1,2,5,6,7,8-
hexahydroquinoline-3-carboxamide
A high analgesic activity of N-(3-pyridylmethyl)-4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydroqui‐
noline-3-carboxamide (16) found during the primary pharmacological screening caused, of
course, an intense interest in it as a potentially new lead compound. However, the second
sample of amide 16 sent to the biological laboratory unexpectedly demonstrated the result
approximately two times lower than the first one. And they both were the products of the same
synthesis! Multiple repeated experiment under the similar conditions for both samples
simultaneously confirmed finally the significant differences in their analgesic properties. At
first there were even doubts that we dealt namely with amide 16 in both cases. But NMR
spectroscopy and combined gas chromatography mass-spectrometry assuaged these doubts
rapidly and confirmed the absolute identity of the first and second samples.
Amide 16 is insoluble in water and it was introduced orally to the experimental animals as a
fine aqueous suspension stabilized by Tween-80. Since the tested substance entered the
organism as a solid, then the crystalline structure became one of the most probable factors
influencing considerably on its biological properties [48]. The tendency of many substances to
form various crystalline modifications (polymorphism) has attracted the attention of scientists
for a long time. In particular, drug polymorphism is capable to change their characteristics so
cardinally that currently all serious pharmaceutical manufacturers can not ignore this problem.
And the government regulatory authorities also pay attention to the issues of obtaining,
determination, description, purity and properties of crystalline forms of products used in
pharmacy. As a result – today registration of a new drug in many countries of the world has
become impossible without such information. It should, however, be recognised that although
polymorphism has turned into an individual science, but it still remains an unsolved phe‐
nomenon of nature to a large extent. Until the present researchers only state the fact of
formation of one or another polymorphic modifications of a substance. For the present one
fails to predict theoretically or calculate this process and, particularly, predetermine conditions
providing formation only the necessary polymorph.
Taking into account the given data we consider expedient to conduct the study of the phase
composition of highly and lower active samples of N-(3-pyridylmethyl)-4-hydroxy-2-
oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide (16) by the methods of X-ray powder and
single-crystal X-ray structural analysis. Tailing of most peaks on the X-ray powder diffraction
patterns complicated their analysis greatly and allowed to state with certainty only the fact
that each sample consisted of several phases in various ratios. A thorough microscopic analysis
led to similar results, but at the same separate shiny triclinic crystals suitable for conducting
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the single-crystal X-ray structural research were observed in the total powder mass of the active
sample (Figure 6).
Figure 6. The structure of 1,2,5,6,7,8-hexahydroquinoline-3-carboxamide 16 molecule with numbering of the atoms
In the independent part of the elementary cell of this crystalline phase of amide 16 two
molecules – А and В differing in some geometric parameter were found. The cyclohexone
fragment in each of these both molecules is disordered by two half-chair conformations – А1
and А2, В1 and В2 (folding parameters [49]: S = 0.69, Θ = 35.4°, Ψ = 29.9° in А1; S = 0.81, Θ =
34.3°, Ψ = 29.7° in А2; S = 0.87, Θ = 32.3°, Ψ = 25.1° in В1; S = 0.57, Θ = 39.4°, Ψ = 28.4° in В2).
Deviation of atoms С(3) and С(4) from the mean-square plane of the rest atoms of the cycle is
-0.34 and 0.34 Å in А1, 0.40 and -0.40 Å in А2, 0.50 and -0.35 Å in В1 and -0.28 and 0.28 Å in
В2, respectively. The carbamide fragment of the substituent at atom С(8) is in the plane of the
quinolone cycle [the torsional angle is С(7)–С(8)–С(10)–О(3) is -0.3(8)° in А and -4.3(8)° in В]; it is
promoted by formation of intramolecular hydrogen bonds: О(2)–Н…О(3): (Н…О 1.77 Å, О–Н…
О 149° in А, Н…О 1.75 Å, О–Н…О 150° in В) and N(2)–H…O(1): (H…O 2.02 Å, N–H…O 135°
in А, H…O 2.00 Å, N–H…O 135° in В). Formation of the given hydrogen bonds leads to electron
density redistribution in this fragment of the molecule: bonds of О(1)–С(9), О(3)–С(10) and С(7)–
С(8) are extended, and bonds of О(2)–С(7) and С(8)–С(9) are shortened comparing to their mean
values. 3-Picolyl substituent is in the antiperiplanar position in relation to С(8)–С(10) bond [the
torsional angle is C(11)–N(2)–C(10)–C(8) is 173.4(5)° in A and 169.6(5)° in B], and its aromatic cycle
is in –sc-conformation in relation to С(10)–N(2) bond and noticeably turn to N(2)–C(11) bond
[torsional angles are C(10)–N(2)–C(11)–C(12) are -83.7(6)° in A and -78.2(7)° in B; N(2)–C(11)–C(12)–
C(16) -68.6(7)° in A and -69.7(7)° in B]. In the crystal of molecule А and В owing to several
intramolecular hydrogen bonds of С–Н…π stacking-dimers А-А and В-В are formed by the
“head-to-tail” type (the distance between π-systems is 3.8 Å).
In the low active sample of amide 16 such crystalline phase has not found and it is probably
the cause of decrease of its biological activity. This conclusion is not final, of course, since any
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polymorphic modification of amide 16 in the pure form has not been obtained and studied (as,
for example, it was successful in the case of 6-hydroxy-N-(4-methoxyphenyl)-4-oxo-1,2-
dihydro-4Н-pyrrolo[3,2,1-ij]quinoline-5-carboxamide [50] passing clinical trials as a new
quinolone diuretic). The external factors caused the changes of the phase composition of the
second sample are not clear yet. Nevertheless, based on the available data it is definitely
arguable that N-(3-pyridylmethyl)-4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-
carboxamide (16) highly prone to polymorphism. And what's the main – it is not likely
reasonable its further study as a potential pain-killer until at least the conditions, which would
allow obtaining polymorphic modifications of this substance that are entirely highly active in
regard to pharmacology and, not least importantly, with the guarantee of their stability while
storing, are found.
4. Structure, physicochemical and analgesic properties of 4-R-2-oxo-1,2-
dihydroquinoline-3-carboxylic acids
Even skimming of the scientific literature devoted to 4-hydroxyquinoline-2-ones reveals an
extremely wide spectrum of biological properties that are common to these compounds. At
the same time in the range of derivatives of 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbox‐
ylic acids the overwhelming majority of publications is devoted to N-R-amides and products
of their further chemical transformations. Esters are investigated much more rarely and the
data concerning acids are practically absent at all. Meanwhile, being the basis of many N-R-
amides possessing a high analgesic activity, 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-
carboxylic acids themselves also are of a certain interest as possible pain-killers.
4.1. 4-Hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acids and their close analogues
There are few methods for obtaining 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic
acids known at present; moreover, all of them are similar and based on transformation of the
corresponding esters [51]. It is our opinion that the most successful of them is hydrolysis in
the AcOH–HCl–H2O system, which allows to obtain target products with good yields and
purity, as well as to avoid decarboxylation. It is this method that has been used in the synthesis
of 4-ОН-derivatives 17-19 (Figure 7, Table 2). Acids 20a,b unsubstituted in position 4, their 4-
chloro- (20с) and methyl (20g-j) derivatives are much more stable to decarboxylation and can
be obtained by the common alkaline hydrolysis of lower alkyl esters of the corresponding
quinoline-3-carboxylic acids. Only in the case of 4-alkyl- and 4-arylamino derivatives (20е,f)
another synthetic scheme was used – interaction of alkylamines or anilines with 2-oxo-4-
chloro-1,2-dihydroquinoline-3-carboxylic acids [51]
The ionization constants of the compounds synthesized determined by potentiometric titration
show that they all are relatively weak acids. At the same time their dissociation constants
(рКа) by the carboxy group consistently correlate with the influence of substituents present in
the quinolone ring (Table 2). Of special note are 4-amino derivatives: 4-amono group (acid
20d) possessing electron-donor properties decreases acidity of СООН-group so greatly that it
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could not be determined by potentiometric titration (the measurement rang is рКа ~ 14). The
benzyl substituent in 4-amino group (acid 20e) does not change the situation, and only aryl
fragments (for example, 4-chlorophenyl in acid 20f) promote some enhancement of acid
dissociation of carboxyl. By comparison it is notable that many known drugs of nonnarcotic
analgesics group (for example, Diclofenac or Ketorolac, Table 2) are so strong acids, from the
chemical standpoint, that even being as salts they exert the ulcerogenic action and, therefore,
have a lot of contraindications [52].
The study of the analgesic activity of acids 17-20 has been carried out by the method used when
testing 1-N-allylsubstituted amides 6 described above. Thus, the experimental data obtained
testify that in an hour after introduction of the tested compounds the pain threshold increases
in all experimental animals by 7.2-77.3% comparing to the initial level (Table 2). In other words,
in spite of significant differences in the potency of the effect exerted all acids 17-20 without
any exception reveal analgesic properties. Thus, if the first representative of 4-hydroxy
derivatives group – acid 17a – does not yield Diclofenac in its activity, then introduction of N-
alkyl, benzyl or phenyl substituents (acids 17b-g) leads to the marked decrease of the analgesic
action. At the same time carbamoylethyl derivative 17h exceeds all the reference drugs used,
including the narcotic analgesic Tramadol, by its analgesic effect.
In most cases modification of the benzene moiety of 4-hydroxy-2-oxo-1,2-dihydroquinoline
ring (acids 17i-o, 18, 19) negatively reflects on biological properties. Nevertheless, highly active
compounds have been also found in this range. For example, 6-bromo-4-hydroxy-2-oxo-1,2-
dihydroquinoline-3-carboxylic acid (17l) appeared to be a more powerful pain-killer than
Tramadol. It is interesting that 6-bromo derivative appeared to be also the most active in the
case of picolyl-3-amides 14 (see Table 1). However, additional bromine atom in position 8 (acid
17m) almost completely deprives the molecule of analgesic properties. 4-Hydroxy-2-
oxo-1,2,5,6,7,8-hexahydro- and 1-allyl-4-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic
acids (18 and 20i, respectively) exceeding nonnarcotic analgesics Diclofenac and Ketorolac by
specific activity and yielding Tramadol a little are also worthy.
However, of all 4-R-2-oxo-1,2-dihydroquinoline-3-carboxylic acids 17-20 considered we think
4-benzylamino derivative 20e attracts the most interest. With its high analgesic activity this
compound is surprisingly a very weak acid. That is why unlike Diclofenac and Ketorolac there
should not be any serious gastrointestinal disorders with its possible medical application (at
least in such pronounced form).
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Figure 7. 2-Oxo-1,2-dihydroquinoline-3-carboxylic acids
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Compound R R' pKaCOOH
Analgesic activity
(increase of the pain
threshold, %)
17a H H 7.16 34.1
17b Me H 7.49 28.6
17c Et H 7.53 13.9
17d All H 7.30 14.4
17e Pr H 7.61 7.8
17f Bn H 7.15 17.2
17g Ph H 6.91 17.0
17h CH2CH2CONH2 H 7.06 77.3
17i H 6-F 6.87 10.4
17j H 6-Cl 6.76 7.2
17k H 7-Cl Insoluble 13.8
17l H 6-Br 6.69 69.1
17m H 6,8-Br2 5.69 8.7
17n H 6-I 6.63 34.6
17o H 6,7-(OMe)2 7.68 10.4
18 – – 8.25 54.9
19a (CH2)2 H 7.20 17.1
19b (CH2)3 H 7.61 8.7
19c (CH2)2CH(Me) 9-F 7.32 15.9
20a H H 8.74 30.5
20b Pr H 8.99 21.2
20c Et Cl 6.29 8.7
20d H NH2 > 14 52.4
20e H NH-Bn > 14 75.4
20f H NH-C6H4-Cl(4) 10.48 19.6
20g H Me 7.15 36.7
20h Et Me 7.10 33.4
20i All Me 6.95 51.5
20j Pr Me 7.17 15.6
Diclofenac (10 mg/kg) 4.15 34.1
Ketorolac (10 mg/kg) 3.49 46.4
Tramadol (25 mg/kg) - 57.2
Table 2. Acidic and analgesic properties of 2-oxo-1,2-dihydroquinoline-3-carboxylic acids 17-20
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4.2. 4-N-R-Substituted 2-oxo-1,2-dihydroquinoline-3-carboxylic acids and functional
derivatives thereof
Naturally the combination of characteristics of 4-benzylamino-2-oxo-1,2-dihydroquinoline-3-
carboxylic acid (20e) that are important for a possible future drug have not gone unnoticed.
This compound is of a real interest as an intermediate leading structure in the search of
potential pain-killers with improved properties. With the purpose of revealing the structural
fragments affecting the most actively manifestation of analgesic properties the synthesis of
series of the closest analogs of this compound and their pharmacological screening have been
carried out.
The first representative of modified derivatives was 4-benzylaminoquinoline-2-one (21, Figure
8) obtained readily by decarboxylation of the parent structure 20e or by the reaction of 4-
chloro-2-oxo-1,2-dihydroquinoline-3-carboxylic acid with benzylamine in high-boiling
solvents [53]. As it turned out, removal of the carboxy group from the molecule results in
substantial reduction of the analgesic activity – at the same time the ability to increase the pain
threshold three times decreases comparing to the initial acid 20e (see Table 3). Esterification
of the carboxy group (ethyl ester 22a), 1-N-ethylation of the quinolone ring (acid 23), as well
as esterification with the simultaneous 1-N-alkylation (1-N-propylsubstituted ester 22b) lead
to the similar consequences. The result obtained is a convincing proof of the essential role of
the carboxy group in exhibiting the biological effect, first of all. Introduction of 1-N-alkyl
substituents, as judged by the examples described, is undesirable; though in general their
impact is not so definite and it can be the subject of further study in principle.
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21 24a-p22a,b 23
Figure 8. Modified analogs of 4-benzylamino-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (20e)
Taking into account the abovementioned facts all our further efforts concerning the chemical
modification of 4-benzylamino-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (20e) were
directed to make changes entirely to the benzyl moiety of its molecule. The synthesis of 4-N-
R-substituted quinoline-3-carboxylic acids 24a-p was carried out according to the scheme of
the same type by interaction of the corresponding primary amines with 4-chloro-2-oxo-1,2-
dihydroquinoline-3-carboxylic acid in boiling ethanol (i.e. under conditions intentionally
excluding the possibility of decarboxylation).
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The chemical modification of the benzyl moiety of acid 20e conducted can be conditionally
divided into three separate directions. The first two deal with separately the methylene unit
or phenyl ring, respectively, the third involves both groupings simultaneously. The pharma‐
cological testing has demonstrated that removal of the methylene bridge separating the
secondary amino group and the aromatic ring (4-N-phenylsubstituted acid 24а) is equal to
decarboxylation described above by its effect on the analgesic properties, i.e. it also results in
about three times decrease of the activity (Table 3). The replacement of the methylene unit by
ethylene and, especially, propylene chains should be also considered unsuccessful. If with
trasfer to 2-phenylethyl derivative 24b the analgesic effect though twice decreases, but still
remains at the level of Diclofenac, then in the case of 3-phenylpropylsubstituted acid 24с it is
practically lost at all.
Methylation of the methylene unit of acid 20e has brought the unexpected results. As a result
of such transformation one asymmetrical carbon atom appears in the molecule, hence, the final
product can be racemic mixture 24d or one of the enantiomers with S- or R-configuration of
the chiral center (24e or 24f, respectively). In the synthesis of these compounds racemic and
optically pure 1-phenylethylamines are used; that is why the structure of aminoquinolines
24d-f obtained on their basis is without any doubt. Depending on the spatial structure of the
biological target and a number of other factors optical antipodes can exert both the same
pharmacological properties and the properties varying so widely. Thus, preservation of the
activity by a racemate usually observed in practice at the same level in the first case and its
essential decrease or even its complete loss in the second case are quite logical. In this connec‐
tion a rather high analgesic activity of racemic 1-phenylethylsubstituted quinoline-3-carbox‐
ylic acid 24d on the background of optically pure enantiomers 24e and 24f that are absolutely
inert in biological respect appears to be somewhat unexpected. The test substances introduced
to the experimental animals as aqueous suspensions are insoluble in water and that is why it
is not improbable that the cause of the effect found is in differences of crystalline forms. But
the final conclusion on this point can be made only after special additional research.
The second direction of the chemical modification of lead compound 20e is represented by 4-
benzylamino-2-oxo-1,2-dihydroquinoline-3-carboxylic acids 24g-n containing substituents in
the aromatic ring of the benzyl fragment. Unfortunately, in all the examples considered a stable
tendency to decrease analgesic properties is observed irrespective to the nature of the sub‐
stituents introduced and their position in the ring (Table 3).
And finally, the third way of modification of 4-N-benzyl substituent of acid 20e intending
introduction of changes into the methylene unit and the aromatic ring simultaneously is
presented only by two compounds – optically active 4-[1-(4-methoxyphenyl)-ethylamino]-2-
oxo-1,2-dihydroquinoline-3-carboxylic acids 24o and 24p. Here, the influence of the spatial
configuration of asymmetric carbon on the strength of the analgesic effect is clearly visible: S-
enantiomer 24o is noticeably more active than its R-antipode 24p. It is also interesting to note
the fact that the methyl group introduced separately into the methylene unit (acid 24е) or 4-
methoxy introduced into the aromatic ring (acid 24l) lead to the complete loss of the analgesic
properties by basic structure 20e. However, the effect of the same substituents introduced
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simultaneously is not any more categorical. In particular, the activity of acid 24o remains
unchanged at the level of one of the most powerful nonnarcotic analgesics Ketorolac.
Thus, according to the results of the research performed the conclusion can be made that in
the structure of 4-benzylamino-2-oxo-1,2-dihydroquinoline-3-carboxylic acids the carboxy
group plays a key role in the process of binding with receptors beyond any doubt. The benzyl
group is one more important structural fragment providing a large interaction with a biological
target. At the same time the role of 1-N-alkyl substituents is not so simple and requires more
profound study. The significance of the benzene moiety of the quinolone ring, as well as the
secondary amino group in position 4 remains completely unclear.
Compound R X Analgesic activity (increase of thepain threshold, %)
21 – – 24.8
22a H – 18.0
22b Pr – 28.8
23 – – 7.6
24a H none 26.0
24b H (CH2)2 35.2
24c H (CH2)3 7.5
24d H (±) CH(Me) 40.1
24e H S(+) CH(Me) 2.2
24f H R(–) CH(Me) 2.0
24g 4-F CH2 35.0
24h 2-Cl CH2 42.7
24i 4-Cl CH2 18.1
24j 4-Me CH2 20.5
24k 2-OMe CH2 5.8
24l 4-OMe CH2 11.9
24m 3,4-(OMe)2 CH2 28.3
24n 3-O-CH2-O-4 CH2 32.2
24o 4-OMe S(+) CH(Me) 46.1
24p 4-OMe R(–) CH(Me) 31.6
Table 3. Analgesic properties of 4-amino-2-oxo-1,2-dihydroquinolines 21-24 on the model of rectal mucosa irritation
by electric current (p ≤ 0.05)
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4.3. The crystalline structure of 2-oxo-4-(1-phenylethylamino)-1,2-dihydroquinoline-3-
carboxylic acids as the factor that their analgesic activity
When studying biological properties of substances containing asymmetric carbon various
situations are possible such as: enantiomers show the same clinical picture [54]; only one
isomer stipulates the desirable effect, whereas the second one is low active or inactive at all
[55]; enantiomers reveal quite different (sometimes directly opposite) physiological properties
[56]; one of the isomers is unambiguously harmful [57]. It is clear that only in the first case
drugs prepared on the basis of optically active compounds can be racemic mixtures. In all other
situations it is expedient to use one of the enantiomers. However, it should be remembered
that actually sometimes even under the most favorable pharmacological indications in favor
of one of the optical isomers a drug racemate enters the market after all since obtaining the
required optically pure enantiomer presents various difficulties [58].
One more varient of manifestation of biological properties by chiral compounds is theoretically
possible, and it can occur in practice (although quite rarely), when a racemate appears to be
much more active than enantiomers [59]. Frequently this phenomenon is explained by synergy
of effects that are inherent to each of the optical isomers individually (see, for example, a
detailed study of the mechanism of the analgesic action of Tramadol [60]). We came up against
a similar situation while investigating 2-oxo-4-(1-phenylethylamino)-1,2-dihydroquinoline-3-
carboxylic acids 24d-f. However, there are some differences, which can not be explained only
by synergy – racemate 24d (R) appeared to reveal the marked analgesic activity on the
background of enantiomers 24e,f (E) being practically inert in the biological respect. We tried
to find out the cause of this effect in this section.
Acids 24d-f are insoluble in water and introduced orally as aqueous suspensions to the
experimental animals. That is why previously we made an assumption about possible
dependence of the pharmacological action on the crystalline structure of the substances under
study, the more especially as there are many examples of interactions of such kind [48].
The X-ray diffraction analysis has demonstrated that optically pure enantiomers S- and R-
configuration 24e,f obtained independently have the same crystalline structure and, as we
might expect for chiral compounds, they are crystallized in the noncentrosymmetric space
group Р21 [53]. On the contrary, racemate 24d crystallizes in the centrosymmetric space group
Р21/n.
The comparative analysis of the structure of the racemic and enantiomeric molecules (on the
example of an isomer with R-configuration of the chiral center) of 2-oxo-4-(1-phenylethyla‐
mino)-1,2-dihydroquinoline-3-carboxylic acids has show that it is generally rather similar. In
both cases the heterocycle, nitrogen atom N(2), carboxide and carboxy group are in the same
plane with accuracy to 0.02 Å (Figure 9), it is conditioned by formation of two strong intra‐
molecular hydrogen bonds: N(2)–H(2N)…O(2) [H…O 1.81 Å, N–H…O 146° in the enantiomer
structure and H…O 1.74 Å, N–H…O 150° in the racemate] and О(3)–Н(3О)…О(1) [Н…О 1.43 Å,
О–Н…О 148° in E, Н…О 1.59 Å О–Н…О 154° in R]. As a result of formation of hydrogen
bonds a marked electron density redistribution also occurs in the quinolone fragment as
evidenced by bond lengthening of О(1)–С(9) to 1.273(1) Å in E and to 1.268(2) Å in R, О(2)–С(10),
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to 1.234(2) Å in E and to 1.225(2) Å in R comparing to their mean value of 1.210 Å, as well as
the bond of С(7)–С(8) to 1.410(2) Å in E and to 1.418(2) Å in R (the mean value is 1.326 Å). At the
same time some bonds are shortened on the contrary: О(3)–С(10) to 1.316(1) Å in E and to 1.327(2)
Å in R (1.362 Å), С(8)–С(9) to 1.420(2) Å in E and to 1.433(2) Å in R (1.455 Å).
Figure 9. The structure of 2-oxo-4-(1-phenylethylamino)-1,2-dihydroquinoline-3-carboxylic acids 24d-f
The substituent at the amino group is in syn-periplanar conformation in relation to С(6)–С(7)
bond [the torsional angle is C(11)–N(2)–C(7)–C(6) -19.7(2)° in E and -1.6(2)° in R] and turn in such
way that the methyl group is in –ас-orientation in relation to С(7)–N(2) bond in the structure E
and in ар-orientation in R [the torsional angle is C(7)–N(2)–C(11)–C(12) -143.0(2)° in E and 171.3(1)°
in R]. The phenyl substituent is practically perpendicular to С(7)–N(2) bond and somehow turn
to N(2)–C(11) bond in the enantiomer structure [torsional angles are C(7)–N(2)–C(11)–C(13) 94.6(2)°
and N(2)–C(11)–C(13)–C(14) 10.7(2)°]. In the racemate the phenyl substituent is in –sc-conformation
in relation to С(7)–N(2) bond and noticeably turn to N(2)–C(11) bond [torsional angles are C(7)–N(2)–
C(11)–C(13) -67.3(2)° and N(2)–C(11)–C(13)–C(18) -36.3(2)°]. Such position of the substituent at the
amino group leads to appearance of a strong repulsion between it and atoms of the aromatic
cycle of the quinolone fragment [shortened contacts are Н(5)…С(11) 2.46 Å in E and 2.44 Å in R
(the sum of van der Waal radii is 2.87 Å), Н(5)…Н(11) 2.07 Å in E and 1.98 Å in R (2.34 Å), Н(5)
…С(13) 2.42 Å in E and 2.57 Å in R (2.87 Å), Н(11)…С(5) 2.65 Å in E and 2.75 Å in R (2.87 Å), Н(5)
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…С(14) 2.77 Å in R (2.87 Å), С(11)…С(5) 3.09 Å in E and 3.10 Å in R (3.42 Å), С(13)…С(5) 3.30 Å in
E and 3.22 Å in R (3.42 Å)]. As is known [61], the benzene ring is conformationally flexible and
under the influence of the environment can be rather deformable. From these considerations
we have sugested that the steric strain in the enantiomer structure is partially compensated by
disflattening of the aromatic cycle of the quinolone fragment, distortion in some torsional
angle, as well as some pyramidalization of nitrogen atom of the amino group [53]. In the
racemate structure the steric strain is compensated only by the substituent’s deviation at atom
С(7) from the quinolone fragment plane [the torsional angle is C(5)–C(6)–C(7)–N(2) -7.6(2)°]. The
shortened intramolecular contacts of H(2)…H(1N) 2.23 Å in E and 2.29 Å in R (2.34 Å), H(12a)…
H(2N) 2.24 Å in E (2.34 Å), H(12b)…C(18) 2.78 Å in E (2.87 Å) and H(14)…N(2) 2.51 Å in E (2.67 Å)
have been also found in the molecule.
Packing of molecules in crystals of chiral and racemic 2-oxo-4-(1-phenylethylamino)-1,2-
dihydroquinoline-3-carboxylic acids is much more different. For example, molecules of pure
enantiomers form endless zigzag chains in the crystal along the crystallographic line [0 1 0]
owing to intermolecular H-bonding of N(1)-H(1N)…O(2)' (- x, 0.5 + y, 1 - z) H…O 2.15 Å, N–H…
O 148° (Figure 10). In turn, these chains form stacks along the crystallographic line [1 0 0], in
which the distance between the aromatic cycle of the bicyclic fragment and π-system of
carbonyl and carboxy groups of adjacent molecules is 3.37 Å; it allows to suggest the existence
of stacking interaction between them. The intermolecular С–Н…π hydrogen bond of C(16)–H(16)
…C(9)' (x, y, 1 + z) (H…π 2.84 Å, C–H…π 152°) has been also found in the enantiomer crystal.
In the crystal of racemate the molecules of 2-oxo-4-(1-phenylethylamino)-1,2-dihydroquino‐
line-3-carboxylic acid form centrosymmetric dimers owing to intermolecular H-bonding of
N(1)-H(1N)…O(1)' (1 - x, 1 - y, -z) H…O 1.79 Å, N–H…O 175° (Figure 11). The distance between
π-systems of adjacent dimers (3.49 Å), as well as degree of their overlapping allow to assume
the existence of stacking interaction. Adjacent dimers are bound with each other by weak
intermolecular hydrogen bonds of С–Н…π: C(12)–H(12b)…C(10)' (x, 1 + y, z) (H…π 2.81 Å, C–H…
π 130°) and C(11)–H(11)…C(9)' (x, 1 + y, z) (H…π 2.85 Å, C–H…π 145°).
Thus, the research conducted shows the essential distinctions in the crystalline structure of
enantiomeric and racemic 2-oxo-4-(1-phenylethylamino)-1,2-dihydroquinoline-3-carboxylic
acids. It is known [48] that it is this factor that often determines the most important pharma‐
cokinetic determinants of the drug biological action such as bioavailability, distribution in
tissues, metabolic rate, etc. Therefore, it can serve as a prime cause of differences in analgesic
properties of the substances studied. It is evident that specific packing of the racemate
molecules in the crystal promotes their easy bioavailability – hence it is its higher activity. The
satisfactory evidence of this conclusion is the fact that the mechanical racemate of 2-oxo-4-(1-
phenylethylamino)-1,2-dihydroquinoline-3-carboxylic acids obtained by a simple mixing of
equimolar amounts of optically pure enantiomers 24e and 24f without subsequent crystalli‐
zation (it is its fundamental difference from the true single-crystal racemate 24d described
above) is no different by the biological properties from the chiral products composing it. In
other words, bioavailability of enantiomers of 2-oxo-4-(1-phenylethylamino)-1,2-dihydroqui‐
noline-3-carboxylic acid 24e,f remains low irrespective of how they are introduced into the
organism of an experimental animal – individually or as a simple mechanical mixture.
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Figure 10. Zigzag chains formed in the crystal by the molecules of enantiomers 24e,f. The dotted lines indicate the
intermolecular hydrogen bonds
Figure 11. Centrosymmetric dimers formed in the crystal by the molecules of racemate 24d. The dotted lines indicate
the intermolecular hydrogen bonds
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Taking this circumstance into account the research of the phase composition revealing the
biological activity of a single-crystal racemate is of interest. The X-ray phase analysis [62]
performed has demonstrated that the sample is single-phased and fully corresponds to the
racemate’s structure determined for a single crystal. Impurity lines, including those that could
refer to the structure of one of the enantiomers crystallized in group Р21 on the powder
diffraction pattern have not been found. Since the parameters of a primitive unit cell of the
crystals of enantiomer (E) and racemate (R) differ markedly, one may state that the X-ray phase
analysis was carried out with considerably fine precision.
4.4. 4-(Hetarylmethyl)amino-2-oxo-1,2-dihydroquinoline-3-carboxylic acids
The conception of bioisosteric replacements suggested at the beginning of the last century [44]
currently remains one of the most powerful means for creating effective and safe medicines
[40-43]. Its application allows not only to optimize biologically active substances already
known, but to reveal new structures with the similar or related properties and so to enhance
the patent protection of a future drug.
This methodology has proven its value completely while working with 4-hydroxy-6,7-
dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamides (12). That is why we attempted once
more to use it in our research – now for modification of 4-benzylamino-2-oxo-1,2-dihydroqui‐
noline-3-carboxylic acid (20e), which we made by the classical isosteric replacement of the
benzene ring with the heterocycle being similar in many physical and chemical characteristics.
As is known [44], they are pyridine, thiophene and in some way furan.
The  target  4-(hetarylmethyl)amino-2-oxo-1,2-dihydroquinoline-3-carboxylic  acids  25a-f
(Figure 12) have been synthesized by the interaction of the corresponding primary amines
with  4-chloro-2-oxo-1,2-dihydroquinoline-3-carboxylic  acid  [63].  In  parallel  with  hetaryl‐
methyl  amino  substituted  acids  25a-f  cyclohexyl  derivative  25g  has  been  obtained.  Of
course,  this  compound  cannot  be  classed  to  heteroanalogs  of  acid  20e,  however,  the
possibility of finding additional information concerning the key functional groups owing
to it  became a solid ground to its synthesis.  By these reasons the reaction of 4-chloro-2-
oxo-1,2-dihydroquinoline-3-carboxylic  acid  with  some  secondary  amines  has  been  stud‐
ied.  Unfortunately,  the  corresponding  quinoline-3-carboxylic  acids  with  tertiary  amino
groups in position 4 appeared to be extremely unstable substances readily decarboxylized
in  boiling  ethanol  immediately  after  their  formation.  As  a  result,  we  succeded  only  in
isolating 4-N-R,R'-aminoquinolin-2-ones 26 and 27. Nevertheless, there is a benefit from the
experiments carried out. Firstly, they allow to clarify that 4-amino-2-oxo-1,2-dihydroquino‐
line-3-carboxylic acids are relatively stable only with the presence of even one proton in
the amino group. Secondly, the substances obtained are themselves of interest for pharma‐
cological research as a particular type of new structural analogs of the basic molecule. And
still,  the initially entirely specific task set of this experiment – explain the role of 4-NH-
proton in the process of binding of 4-benzylamino-2-oxo-1,2-dihydroquinoline-3-carboxyl‐
ic acid with a biological target – has not be solved yet.
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Figure 12. Heteroanalogues of 4-benzylamino-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (20e)
The analgesic activity of aminoquinolines 25-27 has been studied under conditions being
similar to those in testing quinoline-3-carboxamides 12. Analysis of the data presented in Table
4 shows that our replacement of the aromatic ring of the benzyl fragment in 4-benzylamino-2-
oxo-1,2-dihydroquinoline-3-carboxylic acid by isosteric heterocycle is mainly accompanied
with some decrease in the analgesic properties. In the case of pyridine derivatives the de‐
pendence of the potency of the effect exerted on the position of the nitrogen atom is distinctly
visible. Thus, pyridine-3-ylmethylamine substituted acid 25b does not practically differ from
benzyl analog 20e by its activity, whereas ortho-isomer 25а yields it more than three times.
Benzene has much more similar physical and chemical characteristics with thiophene then
with furan [44]. Therefore, it is quite regular that thiophenemethyl derivative 25f, but not
furfuryl analogs 25d,e, is closer to benzyl prototype 20e by its biological properties.
Compound R
Analgesic activity
(decrease in the
amount of "acetic
acid writhing", %)
Compound R
Analgesic activity
(decrease in the
amount of "acetic
acid writhing", %)
25a 2-Py 21.8 25f Thiophen-2-yl 49.1
25b 3-Py 65.4 25g cyclo-C6H11 46.5
25c 4-Py 34.9 26 – 40.3
25d Furan-2-yl 39.5 27 – 16.2
25e 5-Me-furan-2-yl 39.5 20e 69.8
Table 4. Analgesic properties of aminoquinolines 25-27 on the model of "acetic acid induced writhing" (p ≤ 0.05)
Cyclohexylmethylamine substituted acid 25g deserves individual attention, first of all, because
it maintains rather strong influence on the pain reaction in spite of a significant conformation
rearrangement of 4-N-fragment subjected to modification as compared to a flat benzyl
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prototype. This example testifies the possible perspectives of the given direction development
involving hydrogenized analogs of other molecular systems, including heterocyclic ones, in
the range of the objects studied.
We came to the conclusion of necessity to continue our research after testing 4-N-R,R'-
aminoquinoline-2-ones 26 and 27. The reason for this was a surprisingly high analgesic activity
of 4-(benzylmethylamino)-1Н-quinoline-2-one (26). As previously thought [53], removal of the
carboxy group from the molecule inevitably resulted in the essential decrease of analgesic
properties. However, as it happens, the presence of 3-carboxy group is already not always
necessary for 4-aminoquinoline-2- ones with two substituents in 4-amino group.
5. (4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)acetic acid and its
esters
Pain and inflammation belong to the most widespread signs accompanying numerous
pathological states. To eliminate these manifestations NSAIDs are currently widely used;
among them derivatives of aryl- and hetarylacetic acids – Diclofenac, Aceclofenac, Indometa‐
cin, Clinoril, Etodolac, etc., occupy an important place [14, 52]. In this regard, involvement of
(4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl)acetic acid and its derivatives in searching new
pain-killers conducted by us is logical and regular.
The synthesis of the initial (4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)acetic acid
(28, Figure 13) has been carried out by acylation of methyl N-methylanthranilate with β-
methoxycarbonylpropionyl chloride with subsequent treatment of the intermediate sodium
anilide by methylate in methyl alcohol. The mixture of methyl esters of quinolin-3-yl)acetic
and benzoazepine-4-carboxylic acids formed in the course of this reaction is subjected to
hydrolysis and recyclization into the same final product – (quinolin-3-yl)acetic acid 28 when
treating with the aqueous solution of КОН [64]. Esterification of this compound catalyzed by
acids gives alkyl (4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)acetates (29) with high
yields; they are also of interest for pharmacological testing.
N O
OH
Me
OR
O
N O
OH
Me
OH
O
29a-i28
Figure 13. (4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)acetic acid and its esters
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One of the characteristic criteria of efficiency for anti-inflammatory drugs is the anti-exudative
action. In this regard we began testing the biological properties of the compounds synthesized
with studying their effect on the exudative phase of acute aseptic inflammation. The research
was conducted on the model of carrageenan edema in mice [65]. As a reference drug the classic
nonsteroidal anti-inflammatory drug – Diclofenac in the dose of 8 mg/kg (ED50) was used. The
results obtained show that the initial quinoline acetic acid 28 in the equimolar dose to Diclo‐
fenac can decrease the carrageenan edema size by 23.1% (Table 5). Esterification affects the
anti-exudative properties especially successful. Among the compounds synthesized the
substances, which do not practically yield Diclofenac in their activity (esters 29b,f,h) and even
exceed it somehow (allyl ester 29с) have been found. In this range of compounds the interesting
dependence has been revealed – transfer from esters with the normal O-alkyl chains to
derivatives of the iso-structure is accompanied almost complete loss of the anti-inflammatory
action.
But for the analgesic properties of quinolinylacetic acid 28 and its esters 29 ("acetic acid induced
writhing", p ≤ 0.05, details see Quinoline-3-carboxamides 12) this structural biological regu‐
larity is not already characteristic. Although here most of esters appeared to be much more
active than the initial acid.
Compound R Anti-inflammatoryactivity(edema reduction, %)
Analgesic activity (decrease in the
amount of "acetic acid writhing", %)
28 – 23.1 28.5
29a Me 12.7 64.2
29b Et 45.5 54.4
29c All 52.5 24.1
29d Pr 20.4 33.9
29e i-Pr 3.1 39.3
29f Bu 46.2 50.2
29g i-Bu 27.3 50.2
29h C5H11 44.5 35.9
29i i-C5H11 9.6 22.1
Diclofenac (8 mg/kg) 49.8 –
Diclofenac (5 mg/kg) – 51.6
Table 5. Anti-inflammatory and analgesic properties of quinolinylacetic acid 28 and its esters 29 (p < 0.05)
The X-ray diffraction study of the spatial structure of the most powerful pain-killer from the
esters group – methyl quinolinylacetate 29a – has allowed to determine that the quinolone ring
in the molecule of this compound is incompletely planar: the torsional angle С(1)–N(1)–С(9)–
С(8) is -5.8(2)° (Figure 14). Hence, a shortened intramolecular contact of Н(5)…О(2) 2.40 Å (the
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sum of van der Waal radii 2.46 Å) appears. The methoxycarbonyl fragment of the substituent
at atom С(8) is located orthogonally to the plane of the bicycle and turn a little in relation to C(8)–
С(10) bond [torsional angles are С(7)–С(8)–С(10)–С(11) 93.9(1)° and С(8)–С(10)–С(11)–О(3) -19.7(2)°]. The
methyl group is in ар-conformation in relation to С(10)–С(11) bond [the torsional angle is С(12)–
О(4)–С(11)–С(10) 178.3(1)°].
A rather strong repulsion has been detected between atoms of the methyl group at atom N(1)
and adjacent atoms of the carbonyl group С(9)–О(1) and hydrogen atom in peri-position of the
benzene ring; shortened intramolecular contacts of Н(2)…С(13) 2.53 Å (2.87 Å), Н(2)…Н(13с) 2.27
Å (2.34 Å), Н(13с)…С(2) 2.74 Å (2.87 Å) and Н(13а)…О(1) 2.24 Å (2.46 Å) testify about it.
Figure 14. Structure of the methyl quinolinylacetate 29a molecule with numbering of the atoms
Molecules of methyl quinolinylacetate 29a form endless zigzag chains in the crystal (Figure
15) along the crystallographic line [0 0 1] owing to intermolecular H-bonding of О(2)–Н…О(1)'
(x, 0.5 - y, 0.5 + z) H…O 1.76 Å, O–H…O 160°. It seems that formation of this hydrogen bond
stipulates С(9)–О(1) 1.251(1) Å bond lengthening comparing to its mean value 1.210 Å. The
system of intermolecular С–Н…π hydrogen bonds: C(12)–H(12a)…C(5)' (x, 0.5 - y, -0.5 + z) H…π
2.78 Å, C–H…π 172°; C(13)–H(13a)…C(11)' (x, 0.5 - y, -0.5 + z) H…π 2.84 Å, C–H…π 138° and C(13)–
H(13b)…C(5)' (-x, 1 - y, 1 - z) H…π 2.81 Å, C–H…π 148° has also been found in the crystal.
A comparative analysis of X-ray diffraction data of methyl quinolinylacetate 29a and its ethyl
analog 29b [66] reveals a remarkable resemblance not only the peculiarities of the spatial
structure of these compounds, but their crystalline packing as well. In this connection and
taking into account the abovementioned examples of a significant influence of the crystalline
structure of 4-hydroxyquinolin-2-ones on their biological activity, the related analgesic
properties of esters 29a and 29b are quite logical. In addition, significant differences in the anti-
inflammatory action of these substances are an eloquent evidence of the fact that the crystalline
structure is though important, but not the only factor determining the pharmacological
properties of a substance.
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6. The study of N-(3-pyridylmethyl)-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-
dihydroquinoline-3-carboxamide as a promising pain-killer
According to the results of the primary pharmacological screening only one compound – N-
(3-pyridylmethyl)-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide (12,
R = CH2Py-3) has been selected as a lead compound from the large group of 4-hydroxy-6,7-
dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamides, their closest structural analogs and
some derivatives. After oral introduction to white mice in the dose of 20 mg/kg this compound
is able to reduce the number of writhings caused by intraperitoneal injection of acetic acid by
75.3 % (see Table 1). Picolyl-3-amide 12 has also demonstrated a high activity – 81.1% (р <
0.05) – on the model of ”kaolinic writhings” used for research of the peripheral component of
the analgesic effect [65].
The effect of the lead compound on the central component of the nociceptive system has been
studied in vivo on the models involving the central mechanisms of the pain formation: thermal
or electric irritation of the murine paw, as well as thermal irritation of the rat’s tail and electric
stimulation of the rat’s tailhead [65]. All experiments have been carried out according to the
same scheme: 1 – determination of the initial level of algesthesia in all animals induced by the
appropriate nociceptive irritator; 2 – oral introduction of picolyl-3-amide 12 to the experimen‐
tal animals in the dose of 20 mg/kg and the solvent to the control group of animals; 3 –
monitoring of the pain threshold in every 30 minutes during 5 hours; 4 – calculation of the
analgesic activity comparing to control.
Figure 15. Endless zigzag chains formed in the crystal by molecules of methyl quinolinylacetate 29a. The dotted lines
indicate the intermolecular hydrogen bonds
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It has been found that on the model of the thermal irritation of paws ("hot plate") sensitivity
of mice to pain already decreases by 39.4% in 30 minutes after the beginning of the experiment.
In general the analgesic effect lasts about 4.5 hours reaching its maximum in 75.7% (р < 0.05)
at the point of 2.0 hours. After the change of the thermal irritator by the electric one the picture
observed is practically the same – with the maximum of 90.1% (р ≤ 0.05) during the second
hour and further with smooth decline in activity.
On the model of the thermal irritation of the rat’s tail ("tail flіck") the maximum analgesic effect
– 101.0% (р < 0.05) already develops in 1 hour after introduction of picolyl-3-amide 12 and
retains at ths level during the hour. By the end of testing, i.e. by the 5-th hour, the analgesic
activity consistently decreases though its level still remains rather noticeable (32.4%).
When using electrostimulation of the rat’s tailhead the pain threshold increases not so rapidly
– during the first 30 minutes its growth is only 10.5%. However, further the potency of the
analgesic action quickly grows and by the second hour of the experiment it exceeds the control
indices by 90.9% (р < 0.05), after that it gradually decreases.
A high activity of picolyl-3-amide 12 shown on the models of pains of the central origin allow
to suggest about the receptor mechanism of its analgesic effect. To confirm or dispose this
assumption we carried out a series of experiments in studying the influence of the lead
compound on opioid, adrenergic and dopaminergic receptors. Besides, a possible participation
of GABA-ergic links of the central nociceptive system in the mechanism of its analgesic action
was checked. All investigations of this series were conducted on the model of the thermal
irritation of the rat’s tail ("tail flіck") according the scheme described above with the only
difference that another two groups of animals were added – those taken the known reference
drug and its combination with the new substance under research. In all experiments Picolyl-3-
amide 12 was introduced orally in the dose of 20 mg/kg as a fine aqueous suspension stabilized
by Tween-80. The reference drugs were introduced orally or intraperitoneally in the doses
recommended for each of them [67]. When working with combinations of substances at first
a reference drug was introduced, then in 20 minutes the lead compound was introduced.
As the experiments showed, analgesic effects of picolyl-3-amide 12 demonstrated by it when
taken alone and on background of the preliminary introduction of Naloxone (3.0 mg/kg) differ
slightly (Figure 16). Therefore, the lead compound does not have a substantial effect on opioid
receptors.
The study of the possible participation of the adrenergic system in the mechanism of the
analgesic action of picolyl-3-amide 12 was conducted with the help of α2-adrenoceptor agonist
Clonidine (0.02 mg/kg) and β-adrenergic blocking agent Propranolol (14.5 mg/kg). Analysis
of the data obtained testifies that the lead compound in combination with Clonidine losses the
most part of its initially high analgesic properties – especially during the first 2.5 hours of the
experiment (Figure 17). The same picture can be observed in the case of its combination with
Propranolol (Figure 18). It entitles us to believe that picolyl-3-amide 12 exerts its analgesic
activity through, at least, partial blocking of central α2-adrenoreceptors and activation of β-
adrenoreceptors.
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Figure 16. Lead compound & Naloxone
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Figure 17. Lead compound & Clonidine
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Figure 18. Lead compound & Propranolol
-20
0
20
40
60
80
100
120
0 1 2 3 4
Lead Comp Phenazepamum Phenazepamum  +  Lead Comp
Time, h
An
alg
esi
c a
ctiv
ity
, %
Figure 19. Lead compound & Phenazepamum
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Figure 22. Lead compound & Nifedipine
Differences in analgesic properties of the lead compound, which it exerts with independent
introduction and in combination with Phenazepamum (0.19 mg/kg), in general appeared to
be not so expressed (Figure 19). Thus, the conclusion can be made about its insignificant effect
on the GABA-ergic system.
Participation of picolyl-3-amide 12 dopamine receptors in the mechanism of the analgesic
action has been studied with the help of their blocking agent Chlorpromazine (14.0 mg/kg). In
this case the effect is more expressed than in the previous test. But in general it appeared to be
brief – after gradual increase during the first hour of the experiment it reaches the maximum,
retains this level for about 30 minutes, and then begins to fade (Figure 20).
To study the influence of the lead compound on release of dopamine and noradrenaline in the
CNS the combined medicinal form Nakom® containing Levodopa, a precursor of dopamine,
together with Carbidopa, an inhibitor of its peripheral decarboxylation, was used. If when
introduced alone picolyl-3-amide 12 provides a rapid enhancement of the analgesic properties
till the maximum value during an hour, on the background of Nakom® (24.0 mg/kg) in 30
minutes after the start of testing the growth of activity is sharply discontinued (Figure 21). By
the first hour blocking of the analgesic action of the lead compound achieves approximately
40% and lasts about two hours.
Recently the question about possibilities of creating new pain-killers based on agonists of
neuronal nicotinic acetylcholine receptors (nAChR) is being actively discussed in scientific
literature [68-70]. Epibatidine alkaloid (30, Figure 23) isolated from the extract of the Ecua‐
dorean tree frog skin (Epipedobates tricolor) became the incentive for development of this
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approach. In the experiments in mice this compound revealed 200–500 times higher analgesic
activity than morphine on various experimental models. It is of great importance that analgesia
caused by Epibatidine is not relieved by Naloxone, an opioid receptor antagonist. By its
mechanism of action this natural alkaloid appeared to be a powerful agonist of neuronal
nicotinic acetylcholine receptors regulating different functions of the nervous system [71].
Therefore, it is not surprising that a lot of attention is paid to synthetic representatives of this
group of biologically active substances. The search has been carried out among derivatives of
various nitrogen heterocycles [71]. One of the successful findings was 5-(trifluoromethyl)-6-
(1-methylazepan-4-yl)methyl-1H-quinolin-2-one (31), which exhibited a potent agonist
activity on several human nAChRs [72]. Its structural similarity with 4-hydroxyquinolin-2-
ones studied served as a theoretical prerequisite to testing the influence on nAChR and
picolyl-3-amide 12 offered as a new pain-killer. In this testing a specific nicotinic antagonist
Nifedipine being capable to block effectively the analgesic activity of Epibatidine [71] was
used. During the first hour Nifedipine (102.2 mg/kg) practically had no effect on the analgesic
action of picolyl-3-amide 12 (Figure 22). Then, however, the marked inhibiting effect devel‐
oped rapidly and preserved till the end of the experiment.
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30 31
Figure 23. Natural (30) and synthetic (31) agonists of nicotinic acetylcholine receptors
Reviewing the preliminary results of this piece of our work it is worth mentioning the ability
of picolyl-3-amide 12 to arrest effectively the pains of central and peripheral origin. By its
mechanism of the analgesic action this compound can not be named a selective inhibitor of
one type of receptors. Having no effect on opioid receptors picolyl-3-amide 12 reveals its
analgesic properties mainly via interaction with the adrenergic system and activation of
nicotinic acetylcholine receptors. Other mediator systems, in particular the catecholaminergic
one, are involved to much lesser extent. The GABA-ergic link of the central nociceptive system
participates little in the mechanism of the analgesic action of the lead compound.
The antipyretic action of the lead compound studied on the model of fever in rats caused by
subcutaneous injection of Brewer’s yeast suspension [65] is classified as mild. Picolyl-3-amide
12 did not exert any clinically significant anti-inflammatory effect (the paw edema in mice
induced by subcutaneous injection of 1% formalin solution [65]).
Taking into account the fact that for many drug of the group of nonnarcotic analgesics the
nonselective  inhibition of  prostaglandin biosynthesis  is  characteristic  we have studied a
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possible ulcerogenic action of the lead compound by the known method [65]. As it turned
out, picolyl-3-amide 12 caused visible changes of the gastric mucosa in the half of experi‐
mental mice with a single introduction in very high dose exceeding the therapeutic ones:
UD50 =1582 mg/kg.
Any new potential drug must comply with current high requirements not only by the specific
activity, but safety as well. The study of acute toxicity conducted in white mice has shown that
picolyl-3-amide 12 refers to practically nontoxic substances – its median lethal dose (LD50)
taken orally is 9527 mg/kg.
Thus, N-(3-pyridylmethyl)-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxa‐
mide (12, R = CH2Py-3) has realistic chances to become a medicine and it is recommended to
wide preclinical trials as a promising pain-killer.
7. The latest ideas and findings when creating highly active pain-killers on
the basis of 4-hydroxyquinolin-2-ones and related heterocycles
With the beginning of comprehensive preclinical trials of N-(3-pyridylmethyl)-4-hydroxy-6,7-
dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide the search of new promising com‐
pounds, which are suitable for creation of effective analgesics on their basis, does not naturally
stop. Using the gathered experience we continued working in this direction attracting
mathematical methods in addition to such traditional methods of this sort of investigations as
synthetic, physicochemical and pharmacological ones. Besides, to introduce principally new
substituents in the quinoline ring, as well as diversification of the objects under study due to
heterocycles related in their structure appeared to be very useful and reasonable. In particular,
the extremely interesting direction of searching new pain-killers among 4-hydroxyquinolin-2-
one derivatives was replacement of carbonyl in position 2 to the sulfo group, i.e. transfer to 4-
hydroxy-2,1-benzothiazine 2,2-dioxides.
7.1. QSAR-analysis of the analgesic activity and toxicity of 4-hydroxyquinolin-2-one
derivatives
The search of regularities for the “structure – action” relationship in the range of biologically
active substances is an important stage on the way of purposeful design of new drugs with
the targeted complex of pharmacological properties. In this connection we attempted to
generalize the results of the chemical and biological research conducted with the help of QSAR-
analysis. For this purpose the dependence of the analgesic activity of various 4-hydroxyqui‐
nolin-2-one derivatives on their molecular structure was analyzed according to the definite
scheme consisting of some successive steps.
Formation of learning and test samples. The learning sample is formed from 89 compounds
of various chemical classes: 4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carbox‐
amides (12), some N-(3-pyridylmethyl)-4-hydroxy-2-oxoquinoline-3-carboxamides (14), 4-N-
R,R'-aminoquinolin-2-ones (20е, 25-27) and alkyl (4-hydroxy-1-methyl-2-oxo-1,2-
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dihydroquinolin-3-yl)acetates (29). For external testing of models 17 N-(3-pyridylmethyl)-4-
hydroxy-2-oxoquinoline-3-carboxamides (14-16) and 1-(2-carbamoylethyl)-4-hydroxy-2-
oxo-1,2-dihydroquinoline-3-carboxylic acid (17h) have been used. The analgesic properties of
all compounds have been studied under the same conditions on the model of ”acetic acid
induced writhing”.
Calculation of structural descriptors for all tested compounds. To calculate descriptors two
varients of the molecular structure representation – simplex method (Simplex Representation
of Molecular Structure or SIRMS) [73] and circulation model (CM) [74] were used. Within the
scope of SIRMS the structure is in the form of a set with tetratomic fragments of the fixed
composition, topology and symmetry. The values of physical and chemical characteristics of
atoms, which are important for displaying a property (lipophilicity, particle charges, etc.), are
taken into account when differentiating atoms on simplexes. The structure’s descriptor is the
number of fragments (simplexes) of a certain type. The circulation model of a molecule is a
structure of arbitrary construction in the form of pseudocycle, for which similarity parameters
of Cremer-Pople cycle [75] are calculated; they act as descriptors.
Statistical data processing, selection of significant descriptors. During preprocessing of the
whole array of descriptors those that do not correlate with the property are excluded. Then
analysis of intercorrelating descriptors is carried out. It is evident that pairs of descriptors
correlating among themselves contain the same structural information; therefore, one of these
descriptors can be excluded. Further selection of only significant descriptors is performed from
the rest array with the help of the trend-vector procedure [73].
QSAR models building, their validation and verification with the help of the moving
control procedure and test sample. For building QSAR models the method of partial least
squares (PLS) [73] was used. Its undoubtful advantage is quantitative interpretability of the
"structure – property" dependences obtained. For each group of the descriptors selected
(circulation and simplex) two models were obtained. Their approximation possibilities were
estimated on the basis of determination coefficients (R2), statistical stability (Q2) – with the help
of the procedure of external five-fold cross-validation [73]. The predictive capability of models
was esrimated on the basis of determination coefficients (R2test) for test samples and the mean-
squared prediction error (Stest).
Statistical characteristics of both models are rather high – for simplex descriptors: R2 = 0.95, Q2
= 0.75, R2test = 0.86, Stest = 5.6; for descriptors of the circulation model: R2 = 0.93, Q2 = 0.75, R2test
= 0.81, Stest = 5.1.
These two models are combined in final consensus QSAR model validated by the external test
sample (Table 6) formed from 18 compounds, which have not taken part in model building.
The analysis of the data given in Table 6 shows that the mean forecast error for the analgesic
activity is only 8%. Therefore, the predictive force of the QSAR model obtained is quite
satisfactory and suitable to use for interpretation, out of experimental screening of compounds
previously unstudied and molecular design.
Interpretation of models, estimation of contributions of the physicochemical factors and
structural fragments in the analgesic activity. Application of the PLS method allows to
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estimate quatitatively the contribution of each particular descriptor in the biological activity.
And since a descriptor is the molecule’s fragment taking into account the physicochemical
characteristics of atoms, the possibility to estimate their relative importance appears. This
information is needed for further estimation of the supposed mechanisms of the activity
demonstration, as well as design of new highly active agents.
In the sector diagram (Figure 24) the results of analysis of relative contribution of various
physical and chemical factors to the analgesic activity of 1,2-dihydroquinolin-2-ones deriva‐
tives are presented.
As seen from the given diagram, the electrostatic factors such as partial charges on atoms,
polarizability and lipophilicity have the greatest influence on the analgesic effect. On this basis
it can be assumed that the analgesic activity of 1,2-dihydroquinolin-2-ones is mainly deter‐
mined by their electrostatic interaction with biological targets. The substantial influence of
lipophilicity is obviously connected with transmembrane transfer of molecules to the sites of
their binding with a receptor.
Similarly in the framework of the symplex approach contributions of individual structural
fragments can be calculated and it is possible to determine those that make the maximum
positive contribution in the analgesic activity of compounds from the learning sample.
However, we think, it is much more interesting to perform computation on totally new and
unstudied structures, i.e. to use for the molecular design.
Molecular design of new potentially activepain-killers. With the help of the consensus QSAR
model we performed a purposeful design of new promising analgesics of 4-hydroxyquino‐
line-2-one range. As it is clear from Table 7 where some virtual structures with computed
values of their analgesic action are given, the mathematical assessment of the biological activity
exceeds greatly the minimal (i.e. 50%) efficiency criterion for the pain syndrome relief. We
Compound
Analgesic activity, %
Compound
Analgesic activity, %
Experimental Calculated Experimental Calculated
6 (R = All) 56 47 14m 50 70
12 (R = CH2Py-3) 75 72 14n 75 71
14a 64 68 14o 74 75
14b 60 69 14p 63 72
14g 78 76 14q 59 71
14h 54 63 14r 58 71
14j 63 64 15 45 39
14k 70 74 16 81 61
14l 61 73 17h 60 66
Table 6. The estimation of the predictive force of the QSAR on the external test set
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hope the information will be useful for many medical chemists engaged in the problem of
effective analgesic agents creation.
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Calculated analgesic activity 77% 
Table 7. Virtual quinoline-3-carboxamides and quinoline-3-carboxylates with potentially high activity
Figure 24. The relative impact of physical and chemical factors on the analgesic activity of 1,2-dihydroquinolin-2-ones
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Analysis of toxicity and mutagenicity of highly active compounds. Toxicity and mutagenic‐
ity are the most important characteristics of any biologically active substance. How powerful
specific action a pretender to drug does possess, but without conformance to the current
requirements of safety it can never be allowed to medical application. Hence attempts of
researchers to manage toxicity and mutagenicity of a new potential drug at the early stages of
its development become clearer. Computer prognosis may be quite useful in such cases. For
this purpose the already known QSAR models are suitable [73, 75]. One of them allows
estimating a possible toxicity of compounds in relation to the model infusoria Tetrahymena
pyriformis, another one – their mutagenicity within a framework of Ames test. To characterize
toxicity the following scale has been suggested: -2 < low toxic ≤ 0; 0 < moderately toxic < +1; +1
≤ high toxic. The results of calculation of mutagenicity are of two classes: 0 – non-mutagenic
substances, 1 – mutagenic substances.
According  to  the  mathematical  prognosis  the  most  active  pain-killers  found among the
derivatives  of  1,2-dihydroquinolin-2-ones  belong  to  low  toxic  substances  (Table  8).  Al‐
though calculations confirm our assumption (see section 3.3) about a noticeable increase of
toxicity when introducing a bromine atom in the benzene moiety of the quinolone ring, but
the presence of the atom is still permitted. But the second bromine atom in the molecule
is  extremely  undesirable  –  besides  enhancement  of  toxicity  it  promotes  appearance  of
mutagenicity.
Compound Toxicity Mutagenicity Compound Toxicity Mutagenicity 
N
H
OH
O
N
H
O
N
MeO
MeO
 
- 1.61 0 
N
H
OH
O
N
H
O
N
 
- 1.12 0 
N
OH
O
N
H
O
N
 
- 0.88 0 
N
H
NH
O
COOH
Bn
 
- 1.05 0 
N
H
OH
O
N
H
O
N
Br
 
+ 0.15 0 
N
H
OH
O
N
H
O
N
Br
Br  
+ 0.23 1 
Table 8. Calculated toxicity and mutagenicity of certain 1,2-dihydroquinolin-2-ones
Modeling of active compounds metabolism is one more example of using the obtained QSAR
model in chemical and biological research. Modeling itself is performed by another method,
of course, – in this case transformation of the most active 1,2-dihydroquinolin-2-ones into
virtual metabolites under the influence of the rat liver enzymes has been calculated with the
help of QSAR ToolBox 3.0 software [76]. Only after this the QSAR model suggested by us is
used; with its help the analgesic properties prediction for all theoretically possible metabolites
(Table 9 presents only the small part of them) is performed.
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Compound Possible metabolites 
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Calculated AA   66% 
Table 9. Highly active 1,2-dihydroquinolin-2-ones and their theoretically possible metabolites (AA – analgesic activity)
Such information is rather interesting and important for screening, especially if it is completed
by calculations of the possible toxicity and mutagenicity, and not only leading structures, but
their virtual metabolites as well. It allows to exclude substances, which are capable to transform
into highly toxic or mutagenic products, from candidates to drugs at early stages of screening.
Thus, efficiency of the purposeful search of new pain-killers increases significantly.
7.2. 3-(3-R-Carbamoyl-4-hydroxy-2-oxo-1,2-dihydroquinolin-1-yl)propanenitriles and their
functional derivatives
Aryl- (hetaryl) propanoic acids and their derivatives have an extremely wide spectrum of
biological properties, due to which they have become the base of numerous vital drugs of
different pharmacological group [14, 52]. For example, only among NSAIDs permitted to
medical application and belonging to nonnarcotic analgesics there are about several dozens
of such compounds [46]. Therefore, it is not surprising that further we studied the structures
combined two pharmacologically important fragments in one molecule, namely 4-hydroxy‐
quinolin-2-one and propanoic acid. As one of the variants for the practical solution of this task
we suggested 3-(3-alkylсarbamoyl-4-hydroxy-2-oxo-1,2-dihydroquinolin-1-yl)propaneni‐
triles (32) that are easily avaliable synthetically [77, 78]; as a rule, in the conditions of alkaline
hydrolysis they give the corresponding 3-(3-alkylсarbamoyl-4-hydroxy-2-oxo-1,2-dihydro‐
quinolin-1-yl)propanoic acids with good yields (33, Figure 25) [78].
The analgesic activity for the synthesized compounds of this great series was measured on the
“acetic acid induced writhing” test. The test substances and the reference drug Diclofenac were
administered per os in the form of a thin aqueous suspension stabilized by Tween-80 in the
dose of 5 mg/kg. This dose corresponds to ED50 of Diclofenac exactly for the model of “acetic
acid induced writhing” [39]. The analysis of the research data obtained shows that the great
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majority of the substances investigated actually reveal the marked and statistically valid (р ≤
0.05) analgesic properties.
Thus, from the group of 3-alkylсarbamoyl substituted quinolinyl-propanenitriles 32 some
compounds such as propyl- (32d), iso-butyl- (32g), sec-butyl- (32h), 2-hydroxyethyl- (32u), 3-
chloropropyl- (32x) and 3-methoxypropyl- (32y) amides are of immediate interest, their
analgesic effect does not yield Diclofenac and even exceeds it (Table 10). In general, transfer
from nitriles 32 to the corresponding propanoic acids 33 affects analgesic properties negatively.
However, there some positive exceptions – in the case of allylamide 33c, for example, the
transformation mentioned is accompanied with the substantial intensification of activity. If
the fact that the synthetic precursor of this compound is also highly active is taken into account,
then nitrile 32с → acid 33с bunch can be of interest for further more detailed study.
Such approach for studying 3-(3-R-carbamoyl-4-hydroxy-2-oxo-1,2-dihydroquinolin-1-
yl)propanenitriles appears to be quite logical and reasonable. However, as a minimum, one
important moment was still omitted – intermediate quinolinyl-propaneamides, which form
inevitably during trasformation of nitriles into acids, stay out of sight. Meanwhile, interest to
these compounds rises many times if it is taken into account that in a living organism metab‐
olism of nitriles can be by different ways, including that by the primary hydration to amides
[79, 80]. With regard to the issues in focus it means that the efficiency of any nitrile or amide
as a pain-killer increases greatly if their metabolites also reveal analgesic properties. Therefrom
the idea appeared to involve by all means the intermediate link – quinolinyl-propaneamides
together with initial quinolinyl-propanenitriles and final propanoic acids in the range of the
investigations conducted. This allows to select, first of all, those compounds that besides the
own high analgesic effect will have a rather active metabolite as promising leading structures
from the chain of nitrile → amide → acid.
OH
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NH-Alk
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OH
ON
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COOH
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Figure 25. Quinolinyl-propanenitriles 32, 34, 36, quinolinyl-propanoic acids 33 and quinolinyl-propaneamides 35, 37
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Compound Alk
Analgesic activity (decrease in the amount of "acetic
acid writhing", %)
32 (-CH2CH2C≡N) 33 (-CH2CH2COOH)
a Me 36.3 35.6
b Et 44.2 28.7
c All 59.5 73.3
d Pr 51.0 0
e i-Pr 38.8 40.4
f Bu 18.6 33.2
g i-Bu 62.1 0
h s-Bu 64.3 10.5
i C5H11 38.5 40.7
j i-C5H11 42.1 20.4
k C6H13 47.0 17.9
l C7H15 45.3 16.7
m C8H17 49.4 22.5
n C9H19 42.6 31.3
o C10H21 40.2 16.8
p cyclo-C3H5 43.3 0
q cyclo-C5H9 40.5 22.9
r cyclo-C6H11 48.7 15.2
s cyclo-C7H13 46.4 12.6
t Adamantan-1-yl 31.1 10.5
u CH2CH2OH 51.2 –
v CH2CH2CH2OH 47.3 –
w CH2CH2Cl 24.9 –
x CH2CH2CH2Cl 63.0 –
y CH2CH2CH2OMe 50.6 –
z CH2CH2CH2OPr-i 45.4 –
Diclofenac (5 mg/kg) 52.0
Table 10. The analgesic activity of alkylсarbamoyl substituted quinolinyl-propanenitriles 32 and the corresponding
quinolinyl-propanoic acids 33
To implement this idea the method of selective hydration of 3-(3-R-carbamoyl-4-hydroxy-2-
oxo-1,2-dihydroquinolin-1-yl)propanenitriles to the corresponding propaneamides is re‐
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quired. The task is not so simple than it may seem at first sight since amides primarily formed
are usually subjected to hydrolysis much easier than initial nitriles. As a result, it is not always
possible to stop the reactions of this type at the stage of amides formation. It is for this reason
that the aforementioned alkaline hydrolysis of nitriles 32 to acids 33 is intentionally unsuitable
for obtaining propaneamides.
Compound
R
(CH2)n
Analgesic activity (decrease in the amount of "acetic
acid writhing", %)
34 (-CH2CH2C≡N) 35 (-CH2CH2CONH2)
a PhCH2 54.4 –
b cyclo-C6H11CH2 29.3 –
c 2-FC6H4CH2 20.3 38.3
d 4-FC6H4CH2 67.1 36.4
e 2-ClC6H4CH2 16.5 0
f 4-ClC6H4CH2 0 56.0
g 2-MeC6H4CH2 39.2 40.9
h 3-MeC6H4CH2 18.0 41.1
i 4-MeC6H4CH2 0 28.6
j 2-MeOC6H4CH2 38.1 –
k 4-MeOC6H4CH2 34.8 35.5
l 3,4-(MeO)2C6H3CH2 0 39.2
m Piperonyl 0 14.7
n (±) PhCH(Me) 16.1 47.8
o S(-) PhCH(Me) 10.6 46.1
p R(+) PhCH(Me) 21.7 47.0
q (±) 4-MeOC6H4CH(Me) 46.6 –
r S(-) 4-MeOC6H4CH(Me) 17.3 –
s R(+) 4-MeOC6H4CH(Me) 22.5 –
t PhCH2CH2 55.3 –
u 3-ClC6H4CH2CH2 42.6 –
v 4-ClC6H4CH2CH2 23.4 –
w 4-MeOC6H4CH2CH2 64.6 35.7
x 3,4-(MeO)2C6H3CH2CH2 39.5 20.8
y PhCH2CH2CH2 46.6
Diclofenac (5 mg/kg) 57.2
Table 11. The analgesic activity of arylalkylсarbamoyl substituted propanenitriles 34 and the corresponding
propaneamides 35
We succeeded to find the effective method of transformation of 3-(3-arylalkylсarbamoyl-4-
hydroxy-2-oxo-1,2-dihydroquinoline-1-yl)propanenitriles (34) into the corresponding pro‐
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paneamides 35 with the help of a simple and available reagent – the mixture of hydrochloric
and acetic acids with the low content of water [81]. The method is interesting by the fact that,
if required, it allows to perform more profound chemical transformations – for example,
hydrolysis of nitriles in amides – only by increasing the reaction duration.
Compound CH2-Ht
Analgesic activity (decrease in the amount of "acetic
acid writhing", %)
36 (-CH2CH2C≡N) 37 (-CH2CH2CONH2)
a Picolyl-2 72.3 47.0
b Picolyl-3 36.6 10.2
c Picolyl-4 21.0 31.2
d Furfuryl 0 –
e 5-Me-furfuryl 59.8 –
f Tetrahydrofurfuryl 15.4 0
g Thiophen-2-ylmethyl 0 –
Diclofenac (5 mg/kg) 44.3
Table 12. The analgesic activity of hetarylalkylсarbamoyl substituted propanenitriles 36 and the corresponding
propaneamides 37
Comparison of analgesic properties of the obtained triad of arylalkylсarbamoylsubstituted
propanenitriles, propaneamides and propanoic acids allows to assert that, as a rule, the acid
appears to be the least active in the chain of nitrile → amide → acid. Thus, further we focused
our efforts on studying only nitriles and amides. It follows from the data given in Tables 11
and 12 that often quinolinyl-propaneamides actually demonstrate higher analgesic properties
than their synthetic precursors. Therefore, it is expedient to perform the further search of
potential pain-killers in the range of the compounds studied among 1-(2-cyanoethyl)- and 1-
(2-carbamoylethyl)-quinolines. Furthermore, with transfer from acids to amides or nitriles
acidity decreases essentially, as well as probability of manifestation of the ulcerogenic action
being a serious drawback of many modern analgesics.
By the available data from the whole group of quinolinyl-propanoic acids derivatives studied
so far, in addition to the abovementioned allyl substituted nitrile 32с, 1-(2-cyanoethyl)-N-(2-
pyridylmethyl)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide (36a) deserves atten‐
tion. The basis for this conclusion is a high analgesic activity of not only these nitriles
themselves, but of their possible metabolites as well – acid 33с and amide 37а, respectively.
7.3. 1-R-4-Hydroxy-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamides
Oxicams are an integral part of the range of modern non-steroidal anti-inflammatory drugs
with the marked analgesic effect in the range of their biological activities [14, 46, 52]. Piroxicam
(38, R = 2-Py, Figure 26) became the first commercially successful drug of this group. Later its
more effective analogs – Isoxicam (38, R = 5-Ме-isoxazol-3-yl), Meloxicam (38, R = 5-Ме-
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thiazol-2-yl), etc., appeared at the pharmaceutical market. Today they are widely used by
practical medicine in treating numerous rheumatic and autoimmune human diseases under
the common name of selective inhibitors of cyclooxygenase-2. It is interesting that isomeric
oxicams of 4-hydroxy-1-R-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamides (39), which are
different only by reverse mutual arrangement of atoms of nitrogen and sulfur in the thiazine
cycle, remain practically completely unstudied at present. The cause of the existing situation
is known – it is the absence of effective preparative methods for the synthesis of compounds
of this chemical group.
S N
OH
Me
O O
NHR
O
N S
OH
NH-R'
O
O
O
R
38 39
Figure 26. Oxicams (38) and isomeric 4-hydroxy-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamides (39)
It should be noted that almost half a century ago some 1-N-methyl-substituted carboxanilides
39 were obtained by the reaction of l-methyl-3,4-dihydro-lH-2,l-benzothiazin-4-one 2,2-
dioxide with isocyanates in dimethyl sulfoxide solution with the yields from 28 to 100% [82].
However, because of the low yields at the first two stages of obtaining the initial l-methyl-3,4-
dihydro-lH-2,l-benzothiazin-4-one 2,2-dioxide this four-step synthetic scheme of 1-methyl-4-
hydroxy-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamides 39 appeared to be unattractive.
Furthermore, its application is greatly limited by the necessity of using isocyanates – they are
often expensive or almost unavailable reagents, and it significantly complicates the research
for purposeful search of “structure – property” regularities. As a result, unfortunately, this
undoubtedly interesting work [82] has not got its further development.
Taking these circumstances into account we offer a fundamentally different three-step scheme
for the synthesis of the target 1-R-4-hydroxy-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxa‐
mides 39 suggesting the initial obtaining of alkyl 1-R-4-hydroxy-2,2-dioxo-1H-2λ6,1-benzo‐
thiazine-3-carboxylates; with their subsequent amidation a practically unlimited and freely
available range of various alkyl-, aryl- and hetarylamides can be used.
As was shown earlier, lower alkyl 1-R-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylates
are easily and rapidly amidated by primary and even secondary alkyl-, aryl- and hetaryla‐
mines. At the same time for their high reactivity it is necessary their simultaneous presence in
the pyridinic part of the molecule of both 4-ОН and 2-С=О groups [32]. With the transfer to
alkyl 1-R-4-hydroxy-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxylates the powerful acidifying
effect of the sulfo group so greatly increases 4-ОН-acidity that the ordinary salt formation
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begins to prevent amidation. By comparison – the salts of alkyl 1-R-4-hydroxy-2-oxo-1,2-
dihydroquinoline-3-carboxylates are extremely unstable with amines and rapidly decompose
even by carbon dioxide of the air [83]; and, as a rule, they do not cause problems in amidation.
On the contrary the similar salts of their 2-sulfo analogs can be readily isolated and charac‐
terized. When heating them in the medium of a highly boiling inert solvent they can be
transformed with the high yields into the corresponding 1-R-4-hydroxy-2,2-dioxo-1H-2λ6,1-
benzothiazine-3-carboxamides 39. Although for this purpose several hours are needed,
whereas in case of 2-carbonyl derivatives the similar procedure takes only 3-5 min.
In general, the method offered appeared to be quite effective and with its help we succeeded
in synthesizing a great series of the target alkyl-, arylalkyl-, aryl- and hetarylamides of 1-R-4-
hydroxy-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxylic acids. To confirm their structure
NMR (1Н and 13С) spectroscopy, mass spectrometry, and in some cases X-ray structural
analysis have been used.
The screening study of analgesic properties of 1-R-4-hydroxy-2,2-dioxo-1H-2λ6,1-benzothia‐
zine-3-carboxamides 39 was performed in white nonlinear male rats using the standard model
of "tail flіck" thermal irritation [65]. The substances under research and reference-drugs were
introduced in the dose of 20 mg/kg orally in the form of a fine aqueous suspension stabilized
by Tween-80. The antinociceptive effect was estimated by comparing the duration of the latent
period (the time before tail flick) and in one hour after introduction of the substances studied.
According to the results of the pharmacological research among 1-R-4-hydroxy-2,2-di‐
oxo-1H-2λ6,1-benzothiazine-3-carboxamides 39 synthesized the substances, which exceed
greatly the known drugs both of oxicam range (Piroxicam and Meloxicam) and other chemical
groups (Diclofenac, Ketorolac and even Nalbuphine, narcotic analgesic introduced intraperi‐
toneally) by their analgesic properties have been found. On this basis some of them are
recommended for further profound study as new potential analgesics.
Therefore, the results obtained has demonstrated clearly and convincingly that optimization
of the known drugs by creation of their close structural analogs differing only by inverse
mutual arrangement of atoms or substituents, which we have called “flip-flop drugs” meth‐
odology, is rather interesting, productive and promising for the future.
8. Conclusion
Reviewing the preliminary results of the complex research, which is far from its completion
as yet, even now it is possible to state with certainty that 4-hydroxyquinolin-2-ones have
actually appeared to be practically the inexhaustible source of highly effective pain-killers.
One of these compounds – N-(3-pyridylmethyl)-4-hydroxy-6,7-dimethoxy-2-oxo-1,2-dihydro‐
quinoline-3-carboxamide – possesses important analgesic properties on various experimental
models; it is practically nontoxic, does not have the ulcerogenic action in therapeutic doses,
greatly exceeds many currently known medicines by these parameters and thanks to these
facts it is recommended to wide preclinical trials. Besides, according to the results of QSAR-
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analysis not only relative contributions of some physical and chemical factors and the struc‐
tural fragments to the analgesic activity of 1,2-dihydroquinolin-2-ones have been determined,
but new potentially highly active virtual substances, which are suitable enough for synthesis
and further testing, have been suggested. The primary pharmacological screening has also
found some promising analgesics, but among 3-(3-R-carbamoyl-4-hydroxy-2-oxo-1,2-dihy‐
droquinolin-1-yl)propanenitriles already obtained and 1-R-4-hydroxy-2,2-dioxo-1H-2λ6,1-
benzothiazine-3-carboxamides that are structurally related to them.
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